Pharmaceutical policy reform in Spain
نویسنده
چکیده
Nevertheless, it is clear that some initial steps that will change the institutional foundations of health care financing have been taken. The introduction of the federal fund and the (however limited and contested) convergence between SHI and PHI point to an evolutionary change from competitive corporatism to the marketisation of health care (financing), accompanied by a changing role for state regulation. However, the SHICS-Act also represents a political stalemate in respect of the final design of health care financing (be it citizen’s or flat-rate-insurance) in Germany. Health care financing reform, no doubt, will be a key issue in the electoral campaign of 2009.
منابع مشابه
New Provider Models for Sweden and Spain: Public, Private or Non-profit?; Comment on “Governance, Government, and the Search for New Provider Models”
Sweden and Spain experiment with different provider models to reform healthcare provision. Both models have in common that they extend the role of the for-profit sector in healthcare. As the analysis of Saltman and Duran demonstrates, privatisation is an ambiguous and contested strategy that is used for quite different purposes. In our comment, we emphasize that their analysis leaves questions ...
متن کاملGovernance, Government, and the Search for New Provider Models
A central problem in designing effective models of provider governance in health systems has been to ensure an appropriate balance between the concerns of public sector and/or government decision-makers, on the one hand, and of non-governmental health services actors in civil society and private life, on the other. In tax-funded European health systems up to the 1980s, the state and other publi...
متن کاملDoes the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study
BACKGROUND Healthcare system reform of Sanming city has become a leading healthcare reform model in China. It has developed a rigorous pharmaceutical reform consisted of the Zero Mark-up Drug Policy and the Centralized Procurement of Medicine Policy to bring down drug expenses and total health expenditures. However, despite the credit and much attention have been given to Sanming's pharmaceutic...
متن کاملProvider Governance; A Basic Blackbox Seldom Looked at Properly: A Response to Recent Commentaries
متن کامل
Regulatory Ambivalence and the Limitations of Pharmaceutical Policy in Spain
Broadly speaking, pharmaceutical policy in Spain has been unable to control either the price or the volume of drugs prescribed. Limited attempts have been made to bring together the regulation of the pharmaceutical market and policies, in pursuit of the desired goals of efficiency and quality. This paper assesses the regulation of the Spanish pharmaceutical market over the last two decades by e...
متن کامل